Cargando…

Benefit of psychiatric evaluation on anxiety in patients with Charles Bonnet syndrome

OBJECTIVE: Charles Bonnet syndrome (CBS) is defined as an occurrence of visual hallucinations (VHs) in the absence of any psychiatric/neurological disorder. Significantly reduced vision due to age-related macular degeneration (AMD), cataract or glaucoma is the most common cause for CBS. Aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Doeller, Birgit, Kratochwil, Martin, Sifari, Lena, Hirnschall, Nino, Findl, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907871/
https://www.ncbi.nlm.nih.gov/pubmed/33693058
http://dx.doi.org/10.1136/bmjophth-2020-000463
_version_ 1783655584757710848
author Doeller, Birgit
Kratochwil, Martin
Sifari, Lena
Hirnschall, Nino
Findl, Oliver
author_facet Doeller, Birgit
Kratochwil, Martin
Sifari, Lena
Hirnschall, Nino
Findl, Oliver
author_sort Doeller, Birgit
collection PubMed
description OBJECTIVE: Charles Bonnet syndrome (CBS) is defined as an occurrence of visual hallucinations (VHs) in the absence of any psychiatric/neurological disorder. Significantly reduced vision due to age-related macular degeneration (AMD), cataract or glaucoma is the most common cause for CBS. Aim of this randomized controlled study was to assess whether additional treatment by a psychiatrist is beneficial for patients with CBS. METHODS AND ANALYSIS: Patients with visual acuity of 0.5 LogMAR or worse in the better eye were screened. Instruments used were an interview asking about details of the VH, a mental test and a questionnaire on quality of life. Patients with CBS were randomised into two groups: in group 1, a patient-doctor consultation was performed by an ophthalmologist, and in group 2 a consultation and, if needed, additional medical assessment and treatment was given by a psychiatrist. RESULTS: 4900 patients were screened. 390 patients met the inclusion criteria and among these a CBS prevalence of 34 patients (8.7%) was found. The female-to-male ratio was 4:1 and the average age was 79.3 ± 9.7 years. Four different types of VH were observed: 41% humans (n=14), 32% geometrical shapes/patterns (n=11), 15% plants (n=5) and 12% animals (n=4). The change in quality of life in patients with CBS was not significantly different in both groups (p=0.727, ophthalmologist: n=18, psychiatrist: n=16). CONCLUSION: It is essential for medical staff involved with patients suffering from severe vision loss to be aware of CBS. This will help to better identify and interpret symptoms and could also lead to a more adequate treatment for affected patients. DISCUSSION: It is essential for medical staff involved with patients suffering from severe vision loss to be aware of CBS. This will help to better identify and interpret symptoms and could also lead to a more adequate treatment for affected patients.
format Online
Article
Text
id pubmed-7907871
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-79078712021-03-09 Benefit of psychiatric evaluation on anxiety in patients with Charles Bonnet syndrome Doeller, Birgit Kratochwil, Martin Sifari, Lena Hirnschall, Nino Findl, Oliver BMJ Open Ophthalmol Vision Science OBJECTIVE: Charles Bonnet syndrome (CBS) is defined as an occurrence of visual hallucinations (VHs) in the absence of any psychiatric/neurological disorder. Significantly reduced vision due to age-related macular degeneration (AMD), cataract or glaucoma is the most common cause for CBS. Aim of this randomized controlled study was to assess whether additional treatment by a psychiatrist is beneficial for patients with CBS. METHODS AND ANALYSIS: Patients with visual acuity of 0.5 LogMAR or worse in the better eye were screened. Instruments used were an interview asking about details of the VH, a mental test and a questionnaire on quality of life. Patients with CBS were randomised into two groups: in group 1, a patient-doctor consultation was performed by an ophthalmologist, and in group 2 a consultation and, if needed, additional medical assessment and treatment was given by a psychiatrist. RESULTS: 4900 patients were screened. 390 patients met the inclusion criteria and among these a CBS prevalence of 34 patients (8.7%) was found. The female-to-male ratio was 4:1 and the average age was 79.3 ± 9.7 years. Four different types of VH were observed: 41% humans (n=14), 32% geometrical shapes/patterns (n=11), 15% plants (n=5) and 12% animals (n=4). The change in quality of life in patients with CBS was not significantly different in both groups (p=0.727, ophthalmologist: n=18, psychiatrist: n=16). CONCLUSION: It is essential for medical staff involved with patients suffering from severe vision loss to be aware of CBS. This will help to better identify and interpret symptoms and could also lead to a more adequate treatment for affected patients. DISCUSSION: It is essential for medical staff involved with patients suffering from severe vision loss to be aware of CBS. This will help to better identify and interpret symptoms and could also lead to a more adequate treatment for affected patients. BMJ Publishing Group 2021-02-23 /pmc/articles/PMC7907871/ /pubmed/33693058 http://dx.doi.org/10.1136/bmjophth-2020-000463 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Vision Science
Doeller, Birgit
Kratochwil, Martin
Sifari, Lena
Hirnschall, Nino
Findl, Oliver
Benefit of psychiatric evaluation on anxiety in patients with Charles Bonnet syndrome
title Benefit of psychiatric evaluation on anxiety in patients with Charles Bonnet syndrome
title_full Benefit of psychiatric evaluation on anxiety in patients with Charles Bonnet syndrome
title_fullStr Benefit of psychiatric evaluation on anxiety in patients with Charles Bonnet syndrome
title_full_unstemmed Benefit of psychiatric evaluation on anxiety in patients with Charles Bonnet syndrome
title_short Benefit of psychiatric evaluation on anxiety in patients with Charles Bonnet syndrome
title_sort benefit of psychiatric evaluation on anxiety in patients with charles bonnet syndrome
topic Vision Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907871/
https://www.ncbi.nlm.nih.gov/pubmed/33693058
http://dx.doi.org/10.1136/bmjophth-2020-000463
work_keys_str_mv AT doellerbirgit benefitofpsychiatricevaluationonanxietyinpatientswithcharlesbonnetsyndrome
AT kratochwilmartin benefitofpsychiatricevaluationonanxietyinpatientswithcharlesbonnetsyndrome
AT sifarilena benefitofpsychiatricevaluationonanxietyinpatientswithcharlesbonnetsyndrome
AT hirnschallnino benefitofpsychiatricevaluationonanxietyinpatientswithcharlesbonnetsyndrome
AT findloliver benefitofpsychiatricevaluationonanxietyinpatientswithcharlesbonnetsyndrome